adrenomedullin pegol (BAY 1097761) / Bayer - LARVOL DELTA

Safety and efficacy of inhaled PEG-ADM in ARDS patients: a randomised controlled trial. (PubMed, Crit Care) - P2a/b | "Inhaled PEG-ADM was well tolerated in patients with acute respiratory distress syndrome, but it did not improve clinical outcomes, which led to the early discontinuation after the first part of the trial for futility."

Clinical • Journal • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases • ADM

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=90 | Terminated | Sponsor: Bayer | N=466 ➔ 90 | Trial completion date: Dec 2024 ➔ Dec 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Nov 2024 ➔ Dec 2022; Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=466 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

SEAL: This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b | N=466 | Recruiting | Sponsor: Bayer | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: May 2024 ➔ Nov 2024

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b; N=466; Recruiting; Sponsor: Bayer; Trial completion date: Aug 2023 ➔ Jun 2024; Trial primary completion date: Jul 2023 ➔ May 2024

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Affects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P2a/b; N=466; Recruiting; Sponsor: Bayer; Trial completion date: Feb 2023 ➔ Aug 2023; Trial primary completion date: Jan 2023 ➔ Jul 2023

Clinical • Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Effects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P; N=466; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Respiratory Distress Syndrome • Respiratory Diseases

This Study Collects Information on the Safety of Inhaled Pegylated Adrenomedullin (PEG-ADM), How the Drug is Tolerated and How it Effects Patients Suffering From a Type of Lung Failure That Cause Fluid to Build up in the Lungs Making Breathing Difficult (ARDS) (clinicaltrials.gov) - P; N=466; Not yet recruiting; Sponsor: Bayer

Clinical • New trial • Acute Respiratory Distress Syndrome • Respiratory Diseases

This study collects information on the safety of inhaled pegylated adrenomedullin (PEG-ADM), how the drug is tolerated and how it effects patients suffering from a type of lung failure that cause fluid to build up in the lungs making breathing difficult (ARDS) Tato studie shromažďuje informace o bezpečnosti inhalovaného pegylovaného adrenomedulinu (PEG-ADM), jak je léčivo toler (clinicaltrialsregister.eu) - P2; N=466; Ongoing; Sponsor: Bayer AG

Clinical • New P2 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases